Literature DB >> 7758479

Clinical and bacteriological features of relapsing shunt-associated meningitis due to Acinetobacter baumannii.

H Seifert1, W Richter, G Pulverer.   

Abstract

A case is reported of a patient who developed Acinetobacter baumannii meningitis ten days after a ventriculoperitoneal shunt had been placed for control of elevated intracranial pressure. Intravenous antimicrobial therapy was instituted with imipenem and tobramycin after shunt removal and insertion of a ventriculostomy tube. Following the placement of a ventriculoatrial shunt, clinical and microbiological relapse occurred that was eventually cured after complete removal of the ventricular drainage system and a second course of systemic antibiotics. Relapse was confirmed by modern molecular typing techniques including plasmid DNA fingerprinting and analysis of total genomic DNA by pulsed-field gel electrophoresis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758479     DOI: 10.1007/BF02111872

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

Review 1.  Infections in neurologic surgery. The intraventricular use of antibiotics.

Authors:  D Y Wen; A G Bottini; W A Hall; S J Haines
Journal:  Neurosurg Clin N Am       Date:  1992-04       Impact factor: 2.509

Review 2.  [Imipenem-cilastatin cure of meningitis caused by Acinetobacter calcoaceticus].

Authors:  J F Sánchez; J Sanz-Hospital; A Guerrero; J Martínez-Beltrán; C Quereda
Journal:  Enferm Infecc Microbiol Clin       Date:  1991-10       Impact factor: 1.731

Review 3.  Review of recurrent bacterial meningitis.

Authors:  M W Kline
Journal:  Pediatr Infect Dis J       Date:  1989-09       Impact factor: 2.129

4.  Successful treatment of gram-negative bacillary meningitis with imipenem/cilastatin.

Authors:  K Rodriguez; G M Dickinson; R L Greenman
Journal:  South Med J       Date:  1985-06       Impact factor: 0.954

5.  Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units.

Authors:  C M Beck-Sagué; W R Jarvis; J H Brook; D H Culver; A Potts; E Gay; B W Shotts; B Hill; R L Anderson; M P Weinstein
Journal:  Am J Epidemiol       Date:  1990-10       Impact factor: 4.897

Review 6.  Cerebrospinal fluid shunt infections: a personal view.

Authors:  R Yogev
Journal:  Pediatr Infect Dis       Date:  1985 Mar-Apr

7.  Antimicrobial susceptibility of Acinetobacter species.

Authors:  H Seifert; R Baginski; A Schulze; G Pulverer
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Comparison of four different methods for epidemiologic typing of Acinetobacter baumannii.

Authors:  H Seifert; A Schulze; R Baginski; G Pulverer
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

Review 9.  Nosocomial acinetobacter meningitis secondary to invasive procedures: report of 25 cases and review.

Authors:  Y Siegman-Igra; S Bar-Yosef; A Gorea; J Avram
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

10.  The skin as the source of Acinetobacter and Moraxella species occurring in blood cultures.

Authors:  M S Al-Khoja; J H Darrell
Journal:  J Clin Pathol       Date:  1979-05       Impact factor: 3.411

View more
  3 in total

Review 1.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 2.  Management of meningitis due to antibiotic-resistant Acinetobacter species.

Authors:  Baek-Nam Kim; Anton Y Peleg; Thomas P Lodise; Jeffrey Lipman; Jian Li; Roger Nation; David L Paterson
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

3.  Multidrug Resistance of Acinetobacter Baumannii in Ladoke Akintola University Teaching Hospital, Osogbo, Nigeria.

Authors:  G Odewale; O J Adefioye; J Ojo; F A Adewumi; O A Olowe
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2016-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.